ASCO news

[tarhoosier]

My managing oncologist is Charles Drake in NYC. Most of his effort is in the immunology lab for J&J Medical. At my consultation last week he spoke about this trial which is an outgrowth of his research. The abstract released yesterday. Maximum tolerable dose to be determined. He said that counter to common experience where the side effects increase with dose that in this trial it was the time interval between doses that reduced "treatment effects" or TE but maintained effectiveness, if I understood him correctly. Dose and interval worked different than dose and interval for conventional pharmaceuticals. The key point is there was success with the new ligand and particle.

Actinium 225 is a synthetic (man made) isotope which decays by alpha particle. Alpha radiation delivers high energy to a distance of a few cell diameters.

This is all above my head scientifically but if he is excited then I am as well.

meetings.asco.org/abstracts...

In case the link fails use:

A phase 1 study of JNJ-69086420 (JNJ-6420) as the search term.

[Derf4223]

The interval-between-doses makes sense when a short-lived isotope is used, since I suspect it is important to maintain a dose in situ that stays within certain guardrail values for the duration of the treatment series. If you wait too long between doses, the isotope decays too much.

[Tall_Allen]

I like that it uses an hk2 ligand (which is similar to PSA) instead of a PSMA. I suspect that there will be more cancer vulnerable to it. Bone marrow toxicity is something to watch.

[j-o-h-n]

You know what? The more I'm here the dumber I become.

Good Luck, Good Health and Good Humor.

j-o-h-n

[Sailing-Todd in reply to j-o-h-n]

Glad it’s not just me!😁

[Steel67]

Great find, I know there are many additional targets for both imagining and then transitioning to targeting in development, with many different radioisotopes - this is great progress. I know there is great work going on in Australia with a short half life, quickly eliminated high energy beta isotope, Terbium. They have a couple of different prostate cancer cell targets. These have different levels of toxicity - kidney, hepatic, marrow etc. …so no free lunches, but excellent development. Thanks for sharing.